Advertisement

PentaVision

Retinal Physician

Article

Controversies in Care: The Evidence That Ang-2 Suppression Confers a Clinical Benefit

Is faricimab’s efficacy and extended durability due to its Ang-2 inhibiting properties, or simply the effect of a larger anti-VEGF dose?

By: Michael Colucciello, MD, Arshad M. Khanani, MD, MA, FASRS, Jennifer I. Lim, MD, FARVO, FASRS
Retinal Physician January 1, 2025 Vol 22, Issue January/February 2025 Page(s): 22-26

Clinical Scorecard: Controversies in Care: The Evidence That Ang-2 Suppression Confers a Clinical Benefit

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to clarify the role of Ang-2 in vascular instability and its interaction with Ang-1.
Target Population
Care Setting

Key Highlights

  • highlight_5

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider anti-VEGF therapy as first-line treatment for nAMD, DR, and DME.
    • Monitor treatment response and adjust dosing intervals based on disease activity.
    • Include potential future recommendations for Ang-2 inhibitors.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with retinal diseases requiring intravitreal therapy.

        Faricimab dosing can be extended to every 12 to 16 weeks based on clinical response.

        Clinical Best Practices

        • best_practice_1

        References